Results released
Open the filing on sec.gov
Krystal Biotech, Inc. (KRYS)
Nasdaq: KRYS · Biological Products, (No Diagnostic Substances) · Pittsburgh, PA · filing with the SEC since 2017
Grade7.6
◀ Past 7.1● Present 9.0▶ Future 6.1
The companyfiscal 2025, as filed
Revenue$389M+33.9%
Net income$205M+129.7%
Earnings per share$6.84+128.0%
Operating cash flow$201M+62.7%
Cash$496M+43.9%
Debtn/a
Shareholders’ equity$1.22B+28.9%
Shares, diluted30.0M+0.7%
Return on equity16.8%
The recordfrom its filings
Filings in 202662
Newest filingNov 2 · 8-K
Annual reportFeb 17, 2026
Quarterly reportNov 2, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$105M
Insider buys, 12 months$0.00
Patents granted14
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $470MNet income $225MCash from operations $324Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Quarterly report
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.